Skip to main content
SpringerLink
Log in

Immunologic Aspects of Thyroid Follicular Neoplasms

  • Chapter
Thyroid Cancer

  • 143 Accesses

Abstract

This chapter highlights immunological aspects of cancers arising from thyroid follicular cells, and examines the interplay between the immune system and abnormal thyroid follicular cells that could suppress transformed follicular cells from developing into carcinomas. The role of cytokines secreted by immune cells and how they modulate the function of thyroid carcinoma cells in a manner that could inhibit their growth is discussed, and potential difficulties in the immune response to thyroid carcinoma that could lead to the escape of immune containment are examined. Understanding these difficulties may lead to methods to augment or modify the immune response that could have therapeutic importance. Finally, in this chapter we identify potential routes of immune augmentation or modification of the immune response that could be used therapeutically to suppress thyroid carcinoma. Despite the excellent therapy that has been designed for thyroid carcinoma, many patients still suffer significant morbidity and mortality. Potential immunotherapeutic approaches are not merely conjectural but could have significant clinical importance. Therefore the examination of the immune interaction between effector cells and thyroid carcinoma is an important task to accomplish to define new therapeutic initiatives.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bisi H, Fernandes VSO, De Camargo RYA, Koch L, Abdo AH, De Brito T. The prevalence of unsuspected thyroid pathology in 300 sequential autopsies with special reference to the incidental carcinoma. Cancer 1989; 64: 1888.

    Article  PubMed  CAS  Google Scholar 

  2. Baker Jr JR, Fosso CK Immunological aspects of cancers arising from the thyroid follicular cells. Endocr Rev 1993; 14: 6.

    Google Scholar 

  3. Shull JH, Sharon N, Victor TA, Scanlon EF. Thyroid carcinoma: immunology, irradiation, and lymphocytic infiltration. Arch Surg 1979; 114: 729.

    Article  PubMed  CAS  Google Scholar 

  4. Macen DR, Sullivan MJ, McClatchney KD. Autoimmune thyroiditis: pathophysiology and relationship to thyroid cancer. Laryngoscope 1986; 96: 82.

    Google Scholar 

  5. McConahey WM, Hay ID, Woolner LB, van Heerden JA, Taylor WF. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1979: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 1986; 61: 978.

    Article  PubMed  CAS  Google Scholar 

  6. Clark OH, Greenspan FS, Dunphy JE. Hashimoto’s thyroiditis and thyroid cancer: indications for operation. Am J Surg 1980; 140: 65.

    Article  PubMed  CAS  Google Scholar 

  7. Klitz W. Viruses, cancer and the MHC. Nature 1992; 356: 17–8.

    Article  PubMed  CAS  Google Scholar 

  8. Herberman RB. Cellular immunity In Mendelsohn J (editor). The molecular basis of cancer. Philadelphia: WB Saunders, 1995.

    Google Scholar 

  9. Rigopoulou D, Martinez-Laso J, Martinez-Tello F, Alcaide JF, Benmamar D, Hawkins F, Arnaiz-Villena A. Both class I and class II HLA antigens are thyroid cancer susceptibility factors. Tissue Antigens 1994; 43: 281–285.

    Article  PubMed  CAS  Google Scholar 

  10. Dralle H, Robin-Winn M, Reilmann L, Laue A, Torok M. HLA and Schilddrusencarcinom. KIM Wochenschr 1986; 64: 522.

    Article  CAS  Google Scholar 

  11. Panza N, De Vecchio L, Maio M, De Felice M, Lombardi G, Minozzi M, Zappacosta S. Strong association between an HLA-DR antigen and thyroid carcinoma. Tissue Antigens 1982; 20: 155.

    Article  PubMed  CAS  Google Scholar 

  12. Juhasz F, Boros P, Szegedi G, Balazs G, Suranyi P, Kraszits E, Stenszky V, Farid NR. Immunogenetic and immunologic studies of differentiated thyroid cancer. Cancer 1989; 63: 1318.

    Article  PubMed  CAS  Google Scholar 

  13. Sridama V, Hara Y, Fauchet R, DeGroot U. Association of differentiated thyroid carcinoma with HLA-DR7. Cancer 1985; 56: 1086.

    Article  PubMed  CAS  Google Scholar 

  14. Carter LL, Dutton RW. Relative perforin-and Fas-mediated lysis in Ti and T2 CD8 effector populations. J Immunol 1995; 155: 1028.

    PubMed  CAS  Google Scholar 

  15. Robertson MJ, Manley TJ, Pichert G, Cameron C, Cochran KJ, Levine H, Ritz J. Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leukoc Lymphom 1995; 17: 51.

    Article  CAS  Google Scholar 

  16. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449.

    Article  PubMed  CAS  Google Scholar 

  17. Scherer MT, Ignatowicz L, Winslow GM, Kappler JW, Marrack P. Superantigens: bacterial and viral proteins that manipulate the immune system. Annu Rev Cell Biol 1993; 9: 101.

    Article  PubMed  CAS  Google Scholar 

  18. Amino N, Pysher T, Cohen EP, DeGroot LJ. Immunologic aspects of human thyroid cancer: humoral and cell-mediated immunity and a trial of immunotherapy. Cancer 1975; 36: 963.

    Article  PubMed  CAS  Google Scholar 

  19. LoGerfo P, Feind C, Weber C, Ting W. Immunotherapy of thyroid cancer by induction of autoimmune thyroiditis. Surgery 1983; 94: 959.

    Google Scholar 

  20. Ruggiero V, Latham K, Baglioni C. Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells. J Immunol 1987; 138: 2711.

    Google Scholar 

  21. Ostensen ME, Thiele DL, Lipsky PE. Tumor necrosis-a enhances cytolytic activity of human natural killer cells. J Immunol 1987; 138: 4185.

    PubMed  CAS  Google Scholar 

  22. Pang X-P, Hershman JM, Smith V, Pekary AE, Sugawara M. The mechanism of action of tumour necrosis factor-a and interleukin 1 on FRTL-5 rat thyroid cells. Acta Endocrinol (Copenh) 1990; 123: 203.

    CAS  Google Scholar 

  23. Liaw K-Y, Yao C-C, Chen Y-C, Deng J-S. Impaired cell-mediated immunity function in thyroid cancer. Cancer 1980; 46: 285.

    Article  PubMed  CAS  Google Scholar 

  24. Pujol-Borrell R, Todd I, Doshi M, Bottazzo GF, Sutton R, Gray D, Adolf GR, Feldmann M. HLA class II induction in human islet cells by interferon-γ plus tumour necrosis factor or lymphotoxin. Nature 1987; 326: 304.

    Article  PubMed  CAS  Google Scholar 

  25. Weetman AP, Cohen S, Makgoba MW, Borysiewicz LK. Expression of an intercellular adhesion molecule, ICAM-1, by human thyroid cells. J Endocrinol 1989; 122: 185.

    Article  PubMed  CAS  Google Scholar 

  26. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med 1993; 328: 106.

    Article  PubMed  CAS  Google Scholar 

  27. Kimura H, Yamashita S, Namba H, Tominaga T, Tsuruta M, Yokoyama N, Izumi M, Nagataki S. Interleukin-1 inhibits human thyroid carcinoma cell growth. J Clin Endocrinol Metab 1992; 75: 596.

    Article  PubMed  CAS  Google Scholar 

  28. Rasmussen AK, Bech K, Feldt-Rasmussen U, Poulsen S, Siersbaek-Nielsen K, Friis T, Bendtzen K. The influence of interleukin-1 on the function of in vitro cultured human thyroid cells in monolayers. Acta Endocrinol (Copenh) Suppl 1991; 281: 93.

    Google Scholar 

  29. Ashizawa K, Yamashita S, Tobinaga T, Nagayama Y, Kimura H, Hirayu H, Izumi M, Nagataki S. Inhibition of human thyroid peroxidase gene expression by interleukin 1. Acta Endocrinol (Copenh) 1989; 121: 465.

    CAS  Google Scholar 

  30. Foa R, Guarini A, Gansbacher B. IL2 treatment for cancer: from biology to gene therapy. Br J Cancer 1992; 66: 992.

    Article  PubMed  CAS  Google Scholar 

  31. Asakawa H, Hanafusa T, Kobayashi T, Takai S-I, Kono N, Tarui S. Interferon-y reduces the thyroid peroxidase content of cultured human thyrocytes and inhibits its increase induced by thyrotropin. J Clin Endocrinol Metab 1992; 74: 1331.

    Article  PubMed  CAS  Google Scholar 

  32. Strieter RM, Standiford TJ, Huffnagle GB, Colletti LM, Lukacs NW, Kunkel SL. “The good, the bad, and the ugly”: the role of chemokines in models of human disease J Immunol 1996; 156: 3583.

    CAS  Google Scholar 

  33. Standiford TJ, Kunkel SL, Basha MA, Chensue SW, Lynch JP III, Toews GB, Westwick J, Strieter RM. Interleukin-8 gene expression by a pulmonary epithelial cell line: a model for cytokine networks in the lung. J Clin Invest 1990; 86: 1945.

    Article  PubMed  CAS  Google Scholar 

  34. Strieter RM, Phan SH, Showell HJ, Remick DG, Lynch JP, Genord M, Raiford C, Eskandari M, Marks RM, Kunkel SL. Monokine-induced neutrophil chemotactic factor gene expression in human fibroblasts. J Biol Chem 1989; 264: 10621.

    PubMed  CAS  Google Scholar 

  35. Strieter RM, Kunkel SL, Showell HJ, Remick DG, Phan SH, Ward PA, Marks RM. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-a, LPS, and IL-113. Science 1989; 243: 1467.

    Article  PubMed  CAS  Google Scholar 

  36. Thornton AJ, Strieter RM, Lindley I, Baggiolini M, Kunkel SL. Cytokine-induced gene expression of a neutrophil chemotactic factor/IL-8 in human hepatocytes. J Immunol 1990; 144: 2609.

    Google Scholar 

  37. Strieter RM, Kasahara K, Allen RM, Standiford TJ, Rolfe MW, Becker FS, Chensue SW, Kunkel SL. Cytokine-induced neutrophil-derived Interleukin-8. Am J Pathol 1992; 141: 397.

    PubMed  CAS  Google Scholar 

  38. Koch Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258: 1798.

    Article  Google Scholar 

  39. Weetman AP, Bennett GL, Wong WLT. Thyroid follicular cells produce Interleukin-8. J Clin Endocrinol Metab 1992; 75: 328.

    Article  PubMed  CAS  Google Scholar 

  40. Yoshida M, Matsuzaki H, Sakata K, Takeya M, Kato K, Mizushima S, Kawakita M, Takatsuki. Neutrophil chemotactic factors produced by a cell line from thyroid carcinoma. Cancer Res 1992; 52: 464.

    PubMed  CAS  Google Scholar 

  41. Lawrence DA. Transforming growth factor-beta: an overview. Kidney Int Suppl 1995; 49:S 19.

    Google Scholar 

  42. Ranges GE, Figari IS, Espevik T, Palladino MA Jr. Inhibition of cytotoxic T cell development by transforming growth factor (3 and reversal by recombinant tumor necrosis factor a. J Exp Med 1987; 166: 991.

    Article  PubMed  CAS  Google Scholar 

  43. Ristow HJ. BSC-1 growth inhibitor/type b transforming growth factor is a strong inhibitor of thymocyte proliferation: Proc Natl Acad Sci USA 1986; 83: 5531.

    Article  PubMed  CAS  Google Scholar 

  44. Wrann M, Bodmer S, de Martin R, Siep C, Hofer-Warbinek R, Frei K, Hofer E, Fontana A. T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-13. EMBO J 1987; 6: 1633.

    PubMed  CAS  Google Scholar 

  45. Haapala AM, Soppi E, Morsky P, Salmi J, Laine S, Mattila J. Thyroid antibodies in association with thyroid malignancy: simultaneous occurrence of thyroiditis and thyroid malignancy. APMIS 1994; 102: 390–4.

    Article  PubMed  CAS  Google Scholar 

  46. Barnett PS, McGregor AM Immunologic factors. In: Wheeler MH, Lazarus JH, editors. Diseases of the thyroid. London: Chapman & Hall, 1994; 86–103.

    Google Scholar 

  47. Mazzaferri EL. Thyroid cancer and Graves’ disease. J Clin Endocrinol Metab 1990; 70: 826.

    Article  PubMed  CAS  Google Scholar 

  48. Filetti S, Belfiore A, Amir SM, Daniels GH, Ippolito O, Vigneri R, Ingbar SH. The role of thyroid-stimulating antibodies of Graves’ disease in differentiated thyroid cancer. N Engl J Med 1988; 318: 753.

    Article  PubMed  CAS  Google Scholar 

  49. Belfiore A, Garofalo MR, Giuffrida D, Runello F, Filetti S, Fiumara A, Ippolito O, Vigneri R. Increased aggressiveness of thyroid cancer in patients with Graves’ disease. J Clin Endocrinol Metab 1990; 70: 830.

    Article  PubMed  CAS  Google Scholar 

  50. Ossendorp FA, Bruning PF, Schuuring EMD et al. Thyrotropin dependent and independent thyroid cell lines selected from FRTL-5 tumors grown in nude mice. Endocrinology 1990; 127: 419–430.

    Article  PubMed  CAS  Google Scholar 

  51. Brabant G, Maenhaut C, Kohrle J, Scheumann G, Dralle H, Hoang-Vu C, Hesch RD, von zur Muhlen A, Vassart G, Dumont JE. Human thyrotropin receptor gene: expression in thyroid tumors and correlation to markers of thyroid differentiation and dedifferentiation. Mol Cell Endocrinol 1991; 82: R7.

    Article  PubMed  CAS  Google Scholar 

  52. Dunn JT. Thyroid suppression and medical ablation for differentiated thyroid cancer. Arch Otolaryngol Head Neck Surg 1986; 112: 1207.

    Article  PubMed  CAS  Google Scholar 

  53. Weetman AP. Thyroid peroxidase as an antigen in autoimmune thyroiditis. Clin Exp Immunol 1990; 80: 1.

    Article  PubMed  CAS  Google Scholar 

  54. Kimura S, Hong Y-S, Kotani T, Ohtaki S, Kikkawa F. Structure of the human thyroid peroxidase gene: comparison and relationship to the human myeloperoxidase gene. Biochemistry 1989; 28: 4481.

    Article  PubMed  CAS  Google Scholar 

  55. Yokoyama N, Taurog A, Dorris ML, Klee GG. Studies with purified human thyroid peroxidase and thyroid microsomal autoantibodies. J Clin Endocrinol Metab 1990; 70: 758.

    Article  PubMed  CAS  Google Scholar 

  56. Elisei R, Mariotti S, Swillens S, Vassart G, Ludgate M. Studies with recombinant autoepitopes of thyroid peroxidase: evidence suggesting an epitope shared between the thyroid and the gastric parietal cell. Autoimmunity 1990; 8: 65.

    Article  PubMed  CAS  Google Scholar 

  57. Fabbro D, Di Loreto C, Alberto Beltrami C, Belfiore A, Di Lauro R, Damante G. Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res 1994; 54: 4744.

    PubMed  CAS  Google Scholar 

  58. Portolano S, Chazenbalk GD, Seto P, Hutchinson JS, Rapoport B, McLachlan SM. Recognition by recombinant autoimmune thyroid disease-derived Fab fragments of a dominant conformational epitope on human thyroid peroxidase. J Clin Invest 1992; 90: 720.

    Article  PubMed  CAS  Google Scholar 

  59. Foti D, Rapport B. Carbohydrate moieties in recombinate human thyroid peroxidase: role in recognition by antithyroid peroxidase antibodies in Hashimoto’s thyroiditis. Endocrinology 1990; 126: 2983.

    Google Scholar 

  60. Fragu P, Nataf BM. Human thyroid peroxidase activity in benign and malign thyroid disorders. J Clin Endocrinol Metab 1977; 45: 1089.

    Article  PubMed  CAS  Google Scholar 

  61. De Micco C, Ruf J, Chrestian M-A, Gros N, Henry J-F, Canyon P. Immunohistochemical study of thyroid peroxidase in normal, hyperplastic, and neoplastic human thyroid tissues. Cancer 1991; 67: 3036.

    Article  PubMed  Google Scholar 

  62. Charreire J. Immune mechanisms in autoimmune thyroiditis. Adv Immunol 1989; 46: 263.

    Article  PubMed  CAS  Google Scholar 

  63. Plachov D, Chowdhury K, Walther C, Simon D, Guenet JL, Gruss P. Pax-8, a murine paired box expressed in the developing excretory system and thyroid gland. Development 1990; 110: 643.

    PubMed  CAS  Google Scholar 

  64. Pontius K, Hawk WA. Loss of microsomal antigen in follicular and papillary carcinoma of the thyroid. Am J Clin Pathol 1980; 74: 620.

    PubMed  CAS  Google Scholar 

  65. Yamashita H, Noguchi S, Murakami N, Yokoyama S, Nakayama I. Loss of intracellular peroxidase and anaplastic change of differentiated carcinoma of human thyroid gland. Acta Pathol Jpn 1987; 37: 425.

    PubMed  CAS  Google Scholar 

  66. Neary JT, Nakamura C, Davidson B, Soodak M, Vickery AL Jr, Maloof F. Studies on the membrane-associated nature of human thyroid peroxidase: a difference in the solubility of the enzyme from benign and malignant thyroid tissues. J Clin Endocrinol Metab 1978; 46: 791.

    Article  PubMed  CAS  Google Scholar 

  67. Ohta K, Endo T, Onaya T. The mRNA levels of thyrotropin receptor, thyrogobulin and thyroid peroxidase in neoplastic human thyroid tissues. Biochem Biophys Res Commun 1991; 174: 1148.

    Article  PubMed  CAS  Google Scholar 

  68. Smanik PA, Fithian LJ, Jhiang SM. Thyroid peroxidase expression and DNA polymorphisns in thyroid cancer. Biochem Biophys Res Commun 1994; 198: 948.

    Article  PubMed  CAS  Google Scholar 

  69. Williams ED. The aetiology of thyroid tumors. Clin Endocrinol Metab 1979; 8: 193.

    Article  PubMed  CAS  Google Scholar 

  70. Brabant G, Maenhaut C, Korle J, Scheumann G, Dralle H, Hoang-Vu C, Hesch RD, von zur Muhlen A, Vassart G, Dumont JE. Human thyrotropin receptor gene: expression in thyroid tumors and correlation to markers of thyroid differentiation and dedifferentiation. Mol Cell Endocrinol 1991; 82: R7.

    Article  PubMed  CAS  Google Scholar 

  71. Pilotti S, Collini P, Romualdo DB, Cattoretti G, Pierotti MA, Rilke F. A novel panel of antibodies that segregates immunocytochemically poorly differentiated carcinoma from undifferentiated carcinoma of the thyroid gland. Am J Surg Pathol 1994; 18: 1054.

    Article  PubMed  CAS  Google Scholar 

  72. Lemoine NR, Mayall ES, Wylie FS, Williams ED, Goyns M, Stringer B, Wynford-Thomas D. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989; 4: 159.

    PubMed  CAS  Google Scholar 

  73. Suarez HG, du Villard JA, Severino M, et al. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 1990; 5: 565.

    PubMed  CAS  Google Scholar 

  74. Pinkus GS, Kurtin PJ. Epithelial membrane antigen-a diagnostic discriminant in surgical pathology. Hum Pathol 1985; 16: 929.

    Article  PubMed  CAS  Google Scholar 

  75. Wilson NW, Pambakian H, Richardson TC. Epithelial markers in thyroid carcinoma: an immunoperoxidase study. Histopathology 1986; 10: 815.

    Article  PubMed  CAS  Google Scholar 

  76. Cheifetz RE, Davis NL, Robinson BW, Berean KW, LeRiche JC. Differentiation of thyroid neoplasms by evaluating epithelial membrane antigen, leu-7 antigen, epidermal growth factor receptor and DNA content. Am J Surg 1994; 167: 531.

    Article  PubMed  CAS  Google Scholar 

  77. Yamamoto Y, Izumi K, Otsuka H. An immunohistochemical study of epithelial membrane antigen, cytokeritin and vimentin in papillary thyroid carcinoma. Cancer 1992; 70: 2326.

    Google Scholar 

  78. Si L, Whiteside TL. Tissue distribution of human NK cells studied with anti-Leu-7 monoclonal antibody. J Immunol 1983; 130: 2149.

    Google Scholar 

  79. Ravikumar TS, Steele GD Jr. Modern immunotherapy of cancer. Adv Surg 1991; 24: 41.

    PubMed  CAS  Google Scholar 

  80. Lissoni P, Barni S, Tancini G, Mainini E, Piglia F, Maestroni GJM, Lewinski A Immunoendocrine therapy with low dose subcutaneous IL-2 plus melatonin of locally advanced or metastatic endocrine tumors. Oncology 1995; 52: 163.

    Article  PubMed  CAS  Google Scholar 

  81. Grimm EA, Mazumade RA, Zang HZ. Lymphokine activated killer cell phenomenon: lysis of natural killer resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823.

    Article  PubMed  CAS  Google Scholar 

  82. Rosenberg SA, Spiess PJ, La Freniere R. A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 1986; 223: 1318.

    Article  Google Scholar 

  83. Rosenberg SA, Packard BS, Aebersold PM et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988; 319: 1676.

    Article  PubMed  CAS  Google Scholar 

  84. Vieweg J, Gilboa E. Considerations for the use of cytokine-secreting tumor cell preparations for cancer treatment. Cancer Invest 1995; 13: 193.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. James R. Baker Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine, Washington Hospital Center, Washington, DC, USA

    Leonard Wartofsky MD, MPH, MACP (Chairman, Professor of Medicine and Physiology, Clinical Professor of Medicine, Georgetown, Howard) (Chairman, Professor of Medicine and Physiology, Clinical Professor of Medicine, Georgetown, Howard)

  2. Uniformed Services University of Health Sciences, Washington, DC, USA

    Leonard Wartofsky MD, MPH, MACP (Chairman, Professor of Medicine and Physiology, Clinical Professor of Medicine, Georgetown, Howard) (Chairman, Professor of Medicine and Physiology, Clinical Professor of Medicine, Georgetown, Howard)

  3. George Washington University of Schools of Medicine, Washington, DC, USA

    Leonard Wartofsky MD, MPH, MACP (Chairman, Professor of Medicine and Physiology, Clinical Professor of Medicine, Georgetown, Howard) (Chairman, Professor of Medicine and Physiology, Clinical Professor of Medicine, Georgetown, Howard)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Baker, J.R. (2000). Immunologic Aspects of Thyroid Follicular Neoplasms. In: Wartofsky, L. (eds) Thyroid Cancer. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-199-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-199-2_11

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-6845-9

  • Online ISBN: 978-1-59259-199-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation